An in silico transwell device for the study of drug transport and drug-drug interactions

被引:14
|
作者
Garmire, Lana X.
Garmire, David G.
Hunt, C. Anthony
机构
[1] Univ Calif San Francisco, Dept Biopharmaceut Sci, BioSyst Grp, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Biopharmaceut Sci, UCB Joint Grad Grp Bioengn, San Francisco, CA 94143 USA
[3] Univ Calif Berkeley, Grad Grp Comparat Biochem, Berkeley, CA 94720 USA
[4] Univ Calif Berkeley, Berkeley Sensor & Actuator Ctr, Berkeley, CA 94720 USA
关键词
agent-based modeling; discrete event; drug transport; drug-drug interaction; emergent properties; simulation;
D O I
10.1007/s11095-007-9391-4
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. Validate and exemplify a discrete, componentized, in silico, transwell device (ISTD) capable of mimicking the in vitro passive transport properties of compounds through cell monolayers. Verify its use for studying drug-drug interactions. Methods. We used the synthetic modeling method. Specialized software components represented spatial and functional features including cell components, semi-porous tight junctions, and metabolizing enzymes. Mobile components represented drugs. Experiments were conducted and analyzed as done in vitro. Results. Verification experiments provided data analogous to those in the literature. ISTD parameters were tuned to simulate and match in vitro urea transport data; the objects representing tight junction (effective radius of 6.66 angstrom) occupied 0.066% of the surface area. That ISTD was then tuned to simulate pH-dependent, in vitro alfentanil transport properties. The resulting ISTD predicted the passive transport properties of 14 additional compounds, individually and all together in one in silico experiment. The function of a two-site enzymatic component was cross-validated with a kinetic model and then experimentally validated against in vitro benzyloxyresorufin metabolism data. Those components were used to exemplify drug-drug interaction studies. Conclusions. The ISTD is an example of a new class of simulation models capable of realistically representing complex drug transport and drug-drug interaction phenomena.
引用
收藏
页码:2171 / 2186
页数:16
相关论文
共 50 条
  • [21] DRUG-DRUG INTERACTIONS IN THE NEWBORN
    CONTERAS, EA
    SUTTER, TK
    LOHLA, ER
    PHAN, DK
    NEUROBEHAVIORAL TOXICOLOGY AND TERATOLOGY, 1985, 7 (02): : 204 - 204
  • [22] Drug-drug interactions in urology
    Michel, M. C.
    Schaefers, R. F.
    de la Rosette, J. J. M. C. H.
    UROLOGE, 2009, 48 (03): : 264 - +
  • [23] Drug-drug interactions in the ICU
    S Ray
    M Bhattacharyya
    J Pramanik
    S Todi
    Critical Care, 13 (Suppl 1):
  • [24] COCAINE DRUG-DRUG INTERACTIONS
    SANDS, BF
    CIRAULO, DA
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1992, 12 (01) : 49 - 55
  • [25] Drug-drug interactions - Reply
    DeVane, CL
    JOURNAL OF CLINICAL PSYCHIATRY, 1996, 57 (05) : 225 - 227
  • [26] Predicting drug-drug interactions
    Tucker, GT
    DRUG METABOLISM REVIEWS, 2005, 37 : 5 - 5
  • [27] DRUG-DRUG INTERACTIONS IN HOSPITAL
    MOK, H
    MULPETER, K
    OCONNOR, P
    FEELY, J
    IRISH MEDICAL JOURNAL, 1991, 84 (01) : 26 - 26
  • [28] Drug-drug interactions with antipsychotics
    Meyer, Jonathan
    CNS SPECTRUMS, 2007, 12 (12) : 6 - 9
  • [29] Dolutegravir drug-drug interactions
    Mondleki, E.
    Maartens, G.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2022, 112 (03): : 194 - 195
  • [30] Pharmacodynamic Drug-Drug Interactions
    Niu, Jin
    Straubinger, Robert M.
    Mager, Donald E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (06) : 1395 - 1406